Trial Profile

Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients: TONIC-trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Cisplatin; Cyclophosphamide; Doxorubicin
Indications Advanced breast cancer; Brain metastases; Triple negative breast cancer
Focus Therapeutic Use
Acronyms TONIC

Most Recent Events

22 Mar 2024 Trial design discussed in a poster presentation, presented at 115th Annual Meeting of the American Association for Cancer Research .
24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
21 Mar 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com